Table 2 Clinical trials that target glycolytic metabolism in CRC
Compound | Target | Phases | Combined therapy | Status | Reference |
|---|---|---|---|---|---|
Aspirin | CRLM resection | Phase II/III | NA | Recruiting | NCT00490139 |
Aspirin | MSI-H/dMMR or TMB-H | Phase II | PD-1 antibody | Recruiting | NCT03638297 |
EZN-2208 | Advanced CRC | Phase II |  ± Cetuximab | Unknown | NCT00931840 |
Quercetin | CRC | Not Applicable | Sulindac, Curcumin, Rutin | Terminated | NCT00003365 |
Indisulam | mCRC | Phase II | Capecitabine/Irinotecan | Completed | NCT0016585/NCT00165867 |
FMD | CRC | Not Applicable | Unknown | Completed | NCT03595540 NCT03340935 |
Fasting | CRC | Not Applicable | Chemotherapy | Enrolling by invitation | NCT04247464 |
Ketogenic diet | CRC | Not Applicable | Radiotherapy | Completed | NCT02516501 |